---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-030263"
form_type: "8-K"
ticker: "AIMD"
cik: "0001014763"
company_name: "Ainos, Inc."
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T12:56:02.916396+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Ainos Q2 2024 net loss widens to $3.2M; revenues nil; FCGS trial begins

## Summary
- Revenues nil vs $28,555 YoY as COVID-19 test kit sales ceased; net loss $3,195,022 vs $2,349,727.
- Cash $8,014,098 at June 30, 2024, after $9M convertible note in May and prepayment of senior secured note.
- Enrolled first subject for VELDONA-based FCGS clinical study in July; 30-subject trial aims for Q1 2025 completion.
- Next-Gen Ainos Flora VOC POCT with NVIDIA CUDA targets Q3 design completion, Q4 clinical trial kickoff.
- Operating expenses rose to $3,023,636 from $2,289,336 YoY, driven by co-research, staff, and stock-based compensation.

## SEC filing metadata
- accession: 0001493152-24-030263
- form_type: 8-K
- ticker: AIMD
- cik: 0001014763
- company_name: Ainos, Inc.
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1014763/000149315224030263/0001493152-24-030263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1014763/000149315224030263/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-030263
- JSON: https://secwatch.observer/filing/0001493152-24-030263.json
- Plain text: https://secwatch.observer/filing/0001493152-24-030263.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.